Clinical trials: Over Cancer
Pancreatic Cancer, Surgery
Quality of Life in Elderly Patients After Pancreatic Cancer Surgery
Pancreatic cancer mainly affects the elderly, with over 85% of patients diagnosed after the age of 60 and over half after the age of 70.
- Conditions
- Pancreatic Cancer, Surgery, Elderly
- Trial name
- ADL_DPC_PA (NCT06079229)
- Testing
- Phone call
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Neuroblastoma
Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276731
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- 22 sites in Ireland, United Kingdom
- Sponsor
- Children's Cancer and Leukaemia Group
Non-small Cell Lung Cancer
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC.
- Trial name
- NCT05171777
- Testing
- Atezolizumab
- Where
- 36 sites in United States, Argentina and 10 more
- Volunteers
- 179 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
ABSK021 Food Effect Study in Healthy Subjects
This is a randomized, open-label, two-sequence, two-cycle, cross-over study to evaluate the relative bioavailability of ABSK021 after single-dose fasting and high-fat postprandial administration in healthy subjects
- Trial name
- NCT05280483
- Testing
- ABSK021 with fed state, ABSK021 with fasted state
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Abbisko Therapeutics Co, Ltd
Breast Cancer
Phase II Study in Patients With Operable Breast Cancer
The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and trastuzumab in patients with operable breast cancer. Patients will be treated with the combination for 18 weeks, followed by surgery.
- Trial name
- NCT00518583
- Testing
- Pegylated Liposomal Doxorubicin (Doxil)
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- Aptium Oncology Research Network
Non-muscle Invasive Bladder Cancer
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC).
- Trial name
- NCT06126796
- Testing
- CxBladder Monitor, Cystoscopy
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Mayo Clinic
Neoplasms, Breast
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
This study was originally designed as a Phase III randomized, double blind, placebo controlled study to assess the safety and tolerability, and efficacy of paclitaxel plus trastuzumab plus lapatinib compared with paclitaxel plus…
- Trial name
- NCT00272987
- Testing
- lapatinib, paclitaxel, trastuzumab
- Where
- 16 sites in United States, Belgium
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer, Gastrointestinal Neoplasms
Permission to Collect Blood Over Time for Research
To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease.
- Conditions
- Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00767234
- Testing
- Observation
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Stanford University
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Glioblastoma
A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70
In this study we propose to determine outcomes of patients age 70 or older treated with radiation over 2 weeks given with temozolomide 75 mg/m2 daily during radiotherapy and as a post radiation treatment of 150 mg/m2 - 200 mg /m2…
- Trial name
- NCT01985087
- Testing
- Hypofractionated radiotherapy, Temozolomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Louisville
Castrate Resistant Prostate Cancer
A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)
The management of (castration-resistant) prostate cancer (CRPC) is becoming increasingly complex. The use of peripheral anti-androgens with gonadorelin analogues (maximum androgen blockade) is common place.
- Trial name
- MEL-CAP (NCT01907009)
- Testing
- Melphalan, Lenograstim
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- Barts & The London NHS Trust
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC), and whose tumor cells make a…
- Trial name
- METRIC (NCT01997333)
- Testing
- CDX-011, Capecitabine
- Where
- 140 sites in United States, Australia and 7 more
- Volunteers
- 327 people
- Sponsor
- Celldex Therapeutics
Breast Cancer
Quality of Life and Sexuality of Patients Over 65 Years Undergoing Adjuvant Treatment for Breast Cancer
The purpose of this study is to assess the quality of life and sexuality during adjuvant chemotherapy in over 65 years old patients with breast cancer
- Trial name
- QUALITY-AGE (NCT03946579)
- Testing
- self questionnaires
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Centre Henri Becquerel
Lung Cancer, Tobacco Use Disorder
Standard Medical Care or Urgent Chest X-ray in Diagnosing Lung Cancer in Smokers With Chest Symptoms Who Are Older Than 60 Years
RATIONALE: Diagnostic procedures, such as an urgent chest x-ray, may help in planning cancer treatment. It is not yet known whether standard medical care is more effective than an urgent x-ray in diagnosing lung cancer in smokers…
- Trial name
- NCT01344005
- Testing
- caregiver-related intervention or procedure, questionnaire administration, quality-of-life assessment
- Volunteers
- 386 people
- Sponsor
- Wales Cancer Trials Unit
Depression
Survey on the Clinical Assessment of the Psychological Status of a Patient Over 75 Years Old in Oncology During the Realization of the G8 Score (CADEPO)
The goal of this observational study is to make a statement concerning the identification of depressive symptoms at the time of the realization of the G8 score in patients over 75 with cancer and followed in oncology.
- Trial name
- CADEPO (NCT05681793)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hopital Nord Franche-Comte
Asthma
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent asthma.
- Trial name
- NCT02105012
- Testing
- BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg
- Where
- 41 sites in United States
- Volunteers
- 147 people
- Sponsor
- Pearl Therapeutics, Inc.
Functional Disability, Dementia
Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)
ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with…
- Conditions
- Functional Disability, Dementia, Heart Disease, Stroke
- Trial name
- NCT07224347
- Where
- 36 sites in United States, Australia
- Volunteers
- 19,114 people, healthy volunteers welcome
- Sponsor
- Anne Murray
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
Phase I/II trial to study the effectiveness of combining interleukin-12 with interleukin-2 in treating patients who have mycosis fungoides.
- Conditions
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome
- Trial name
- NCT00052377
- Testing
- aldesleukin, recombinant interleukin-12, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
T Acute Lymphoblastic Leukemia
Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"
T-ALL (T-acute lymphoblastic leukemia) is an aggressive blood cancer, wherein patients who are MRD positive after two courses of induction chemotherapy have poor outcomes.
- Trial name
- DARA_T_ALL (NCT07021677)
- Testing
- Daratumumab Injection
- Where
- India
- Volunteers
- 18 people
- Sponsor
- Tata Memorial Centre
Breast Cancer Stage I, Breast Cancer Stage II
Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer
Phase III, single-center, randomized, double-blind, placebo-controlled, 2x2 cross- over study, assessing the efficacy of CBD in patients with early HR+ BC, presenting aromatase inhibitor-related musculoskeletal pain
- Conditions
- Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, HR+ Breast Cancer
- Trial name
- PANDORA (NCT06787118)
- Testing
- CBD oil
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris